Redenlab selected for world-first international collaboration investigating neurofilament light chain and voice for diagnosing dementia
Repetition assessment for speech and language disorders: A study of the logopenic variant of primary progressive aphasia
Defining effective communication for critically ill patients with an artificial airway: An international multi-professional consensus
2023 Digital Health Innovation in Clinical Trials, Drug Development and Mobile Healthcare: June 6 – 7, 2023
ParkinSong Online: protocol for a telehealth feasibility study of therapeutic group singing for people with Parkinson’s disease
Redenlab Inc. are pleased to announce securing clinical trial in Cyclic Vomiting Syndrome with a Top 10 pharma company. Redenlab are providing audio capture and analytics for a Phase 1b clinical trial. Conducted in sites across the USA, the study will investigate the long-term efficacy of a treatment designed to ameliorate the impact of this rare and debilitating disease.
SpeechATAXIA- a multinational, multilanguage consortia for speech in hereditary ataxias – powered by Redenlab
SpeechATAXIA is a multi-language, multi-national, multi-ataxia consortia designed to measure communication change over time.
Redenlab supporting new randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab are proud to support an upcoming randomized parallel group, placebo-controlled, dose-escalation clinical trial in Ataxia Telangiectasia
Redenlab Inc. are excited to announce securing another clinical trial in Friedreich ataxia. Redenlab are providing speech analytics for a long-term open label extension clinical trial. Conducted in 8 sites across the USA over 2 years, the study will investigate the long-term efficacy of a treatment designed to ameliorate the debilitating impact of this fatal disease. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab Inc, the speech neuroscience company delivering insights in speech and language testing, announces that it has been selected by medium sized USA pharmaceutical company to support their upcoming gene therapy study in Friedreich ataxia (FA). Conducted across 5 sites in 3 countries over 2 years, the Phase 2a study will investigate the safety, tolerability and efficacy of gene therapy on adolescents with FA. For the study, Redenlab will provide advanced speech recording and analysis solutions.
Redenlab chosen for new multinational natural history study in Dentatorubral-pallidoluysian atrophy (DRPLA)
Redenlab are glad to be supporting Larimar Therapeutics Inc. Phase 1 SAD clinical trial is a double-blind, placebo-controlled, randomized clinical trial to assess the safety of subcutaneously administered CTI-1601 versus placebo in adult subjects with Friedreich Ataxia.
Redenlab are proud to be supporting PTC Therapeutics, Inc. Global Phase 3 Clinical Trial to Evaluate Vatiquinone in Friedreich Ataxia.
Describing the relationship between disease severity and speech metrics, through listener-based and objective acoustic analysis.
In our new study, published in the Journal of Acoustical Society of America, we tested reliability, stability, and sensitivity to change in vowel measurements.